FADS1 and hepatocellular carcinoma: When we excluded the first 2 years of follow-up, and further adjusted for lipid-lowering medication, PRS, FADS1/2 genotype, or the remaining plasma fatty acids, the observed associations of specific fatty acids with incident HCC and CLD mortality remained unchanged (Supplementary Tables 12, 13).